This conference will examine the fundamental questions of who pays for biotech innovation and why in this unprecedented environment. It will focus on how the current financing environment and new sources of capital affect business models, development and commercialization strategies.
In doing so, BayBio2010 will consider government initiatives, such as healthcare reform, clean energy legislation and American Recovery and Reinvestment (ARRA) funding, and effects of these programs on therapeutic, diagnostic and clean tech companies.
Additionally, the conference will review new trends in public markets, venture investment, M&A and partnering with larger companies and how they affect the life sciences research and development process. Finally, BayBio2010 will investigate how changing consumer behavior and resulting economic realities factor into biotech company strategies.
For more information, please visit the event website or email Eileen Cheng.